• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Premarket Approval (PMA)

  • Print
  • Share
  • E-mail
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC | Inspections

New Search Back to Search Results
Note: this medical device has supplements. The device description may have changed. Be sure to look at the supplements to get an up-to-date view of this device.
Classification Nameimplantable cardioverter defibrillator (non-crt)
Generic Nameimplantable cardioverter defibrillator
PMA NumberP980023
Date Received06/08/1998
Decision Date10/27/1998
Product Code
LWS[ Registered Establishments with LWS ]
Docket Number 98M-0972
Notice Date 11/18/1998
Advisory Committee Cardiovascular
Expedited Review Granted? No
Combination Product No
Approval Order Statement 
Approval for the phylax implantable cardioverter defibrillator (icd) system: a) icd pulse generator - phylax xm icd, model number 121491; phylax xm active housing icd, model number 121492; phylax xm replacement icd, model number 121162 and mycrophylax icd, model number 121493; b) icd lead - sps 75 lead system, model number 120398; sl-icd lead systems (sl-icd 75/13, model number 120395, sl-icd 75/16, model number 120396, sl-icd 75/18, model number 120397, sl-icd 100/13, model number 116414, sl-icd 100/16, model number 118375, sl-icd118375, sl-icd 100/18, model number 119077); kainox sl lead systems (kainox sl 75/13, model number 124219, kainox sl 75/16, model number 124218, kainox sl 75/18, model number 124217, kainox sl 100/13, model number 124238, kainox sl 100/16, model number 124239, kainox sl 100/18, model number 124240); kainox rv 75 lead system, model number 124005; and (c) programming and monitoring system - tms 1000 tachyarrhythmia monitoring system, and software module swm 1000 f00i01. This device is indicated for use in patients who are at risk of sudden death due to ventricular arrhythmias and have experienced one of the following situations: survival of at least one episode of cardiac arrest (manifested by a loss of consciousness) due to a ventricular tachyarrhythmia; or recurrent poorly tolerated sustained ventricular tachycardia (vt). Note: the clinical outcome for hemodynamically stable vt patients is not fully know. Safety and effectiveness studies for this indication have not been conducted.
Post-Approval StudyShow Report Schedule and Study Progress
Supplements: S001 S002 S003 S004 S005 S006 S007 S008 S009 
S010 S011 S012 S013 S014 S015 S016 S017 S018 
S019 S020 S021 S022 S023 S024 S025 S026 S027 
S028 S029 S030 S031 S032 S033 S034 S035 S036 
S037 S038 S039 S040 S041 S043 S044 S046 S047 
S048 S049 S050 S051 S052 S053 S054 S055 S056 
S057 S058 S059 S060 S061 S062